NCT02173301 - A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

August 31, 2015

Conditions

Psoriasis

Interventions

DRUG

XP23829 400 mg QD

active dose 1

DRUG

XP 23829 800 mg QD

active dose 2

DRUG

XP23829 400 mg BID

active dose 3

DRUG

Placebo

control

Trial Locations (31)

11790

XenoPort Investigational Site, Stony Brook

14623

XenoPort Investigational Site, Rochester

27262

XenoPort Investigational Site, High Point

30078

XenoPort Investigational Site, Snellville

35233

XenoPort Investigational Site, Birmingham

37072

XenoPort Investigational Site, Goodlettsville

40217

XenoPort Investigational Site, Louisville

42303

XenoPort Investigational Site, Owensboro

46032

XenoPort Investigational Site, Carmel

46617

XenoPort Investigational Site, South Bend

48084

XenoPort Investigational Site, Troy

48088

XenoPort Investigational Site, Warren

60089

XenoPort Investigational Site, Buffalo Grove

66215

XenoPort Investigational Site, Overland Park

68114

XenoPort Investigational Site, Omaha

71913

XenoPort Investigational Site, Hot Springs

75230

XenoPort Investigational Site, Dallas

75231

XenoPort Investigational Site, Dallas

75246

XenoPort Investigational Site, Dallas

78218

XenoPort Investigational Site, San Antonio

78229

XenoPort Investigational Site, San Antonio

80210

XenoPort Investigational Site, Denver

84088

XenoPort Investigational Site, West Jordan

85032

XenoPort Investigational Site, Phoenix

92024

XenoPort Investigational Site, Encinitas

92663

XenoPort Investigational Site, Fullerton

94538

XenoPort Investigational Site, Fremont

02111

XenoPort Investigational Site, Boston

02472

XenoPort Investigational Site, Watertown

08520

XenoPort Investigational Site, East Windsor

07044

XenoPort Investigational Site, Verona